Design and Synthesis of 1-Aminocycloalkane-1-carboxylic Acid-Substituted Deltorphin Analogues:  Unique δ and μ Opioid Activity in Modified Peptides

Journal of Medicinal Chemistry
1996.0

Abstract

Deltorphin analogues were substituted by a series of achiral C alpha,alpha-dialkyl cyclic alpha-amino acids (1-aminocycloalkane-1-carboxylic acids, Ac chi c, where chi = a hexane, pentane, or propane cycloalkane ring) in position 2, 3, 4, or 2 and 3 in deltorphin C, and in position 2 in [Ac6c2,-des-Phe3]deltorphin C hexapeptide. Receptor assays indicated that even though Ac6c2 and Ac6c3 exhibited a diminished Ki delta by ca. 20-fold (2.5-3.3 nM) relative to deltorphin C (Ki delta = 0.15 nM), selectivity was marginally elevated (Ki mu/Ki delta = 1250) or enhanced by about 70%, and both peptides fitted stringent iterative calculations for a two-site binding model (eta = 0.625 and 0.766, respectively, P < 0.0001). The disubstituted [Ac6c2,3]- or [Ac6c2,des-Phe3]deltorphin analogues yielded peptides with decreased Ki delta, such that the latter peptide was essentially inactive. The presence of Ac5c or Ac3c in place of Phe3 further diminished Ki delta (15.4 to 19.0 nM), yet delta selectivity only fell about one-half (Ki mu/Ki delta = 440 and 535, respectively), and only the former peptide fitted a two-site binding model (eta = 0.799). The replacement of Asp4 by Ac6c, Ac5c, or Ac3c produced essentially nonselective analogues through the acquisition of high mu affinities (2.5, 0.58 and 0.27 nM, respectively) while maintaining high delta affinities (Ki delta = 0.045-0.054 nM) which were about 3-fold greater than that of deltorphin C. Using pharmacological assays in vitro (mouse vas deferens and guinea pig ileum), position 3-substituted analogues all indicated substantial losses in bioactivity, whereas substitution by 1-aminocycloalkanes at the fourth position retained high delta activity. In fact, the bioactivity of [Ac3c4]deltorphin C indicated a peptide with relatively weak delta selectivity, which was comparable to the observations with the receptor binding data. In summary, the data confirmed that (i) delta selectivity occurs in the absence of D-chirality at position 2, (ii) the aromaticity of Phe3 is replaceable by an achiral residue with a hydrophobic ring-saturated side chain, and (iii) the acquisition of dual high-affinity analogues occurs through the elimination of the anionic function at position 4 and replacement by an amino acid with a hydrophobic side chain.

Knowledge Graph

Similar Paper

Design and Synthesis of 1-Aminocycloalkane-1-carboxylic Acid-Substituted Deltorphin Analogues:  Unique δ and μ Opioid Activity in Modified Peptides
Journal of Medicinal Chemistry 1996.0
Phe3-substituted analogs of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by .delta. opioid receptors
Journal of Medicinal Chemistry 1993.0
Helix-Inducing α-Aminoisobutyric Acid in Opioid Mimetic Deltorphin C Analogues
Journal of Medicinal Chemistry 1997.0
Conformationally restricted deltorphin analogs
Journal of Medicinal Chemistry 1992.0
Opioid Receptor Binding Requirements for the .delta.-Selective Peptide Deltorphin I: Phe3 Replacement with Ring-Substituted and Heterocyclic Amino Acids
Journal of Medicinal Chemistry 1995.0
Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogs with high selectivity for .delta.-opioid receptors
Journal of Medicinal Chemistry 1994.0
Para-substituted Phe3 deltorphin analogs: enhanced selectivity of halogenated derivatives for .sigma. opioid receptor sites
Journal of Medicinal Chemistry 1992.0
Function of negative charge in the "address domain" of deltorphins
Journal of Medicinal Chemistry 1991.0
Substitution on the Phe3 aromatic ring in cyclic .delta. opioid receptor-selective dermorphin/deltorphin tetrapeptide analogs: electronic and lipophilic requirements for receptor affinity
Journal of Medicinal Chemistry 1992.0
Topographical requirements for delta opioid ligands: The synthesis and biological properties of a cyclic analogue of deltorphin I
Bioorganic &amp; Medicinal Chemistry Letters 1992.0